The San Diego-based genotyper made $16 million, or 32 cents a share, for the quarter ended Oct. 1, reversing the year-ago loss of $1.4 million, or 3 cents a share. Analysts surveyed by Thomson Financial were looking for a 16-cent profit.
Sales rose 174% from a year ago and 29% sequentially, hitting $53.5 million. Analysts were looking for $47 million.
For the fourth quarter, Illumina expects to make at least 31 cents a share on sales of around $56 million. Analysts were looking for 17 cents on $50 million.
Shares rose $5.32 to $42.